The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Immuno-oncology and the future of multiple myeloma treatment
Jesús San Miguel, MD, Universidad de Navarra, Navarra, Spain, discusses the emergence of chimeric antigen receptor (CAR) T-cell therapies and bispecific monoclonal antibodies, and the encouraging data being seen from trials in patients with multiple myeloma. CAR T-cell therapy and bispecific antibodies may be of particular benefit for patients that are refractory to lenalidomide. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
